Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Dual data displays
September 2020
SHARING OPTIONS:

CAMBRIDGE, Mass.—The 2020 American Association for Cancer Research Virtual Annual Meeting II saw, among other companies, Kymera Therapeutics Inc. share preclinical data on two programs: one of its STAT3 degraders and the first data from its novel IRAKIMiD degraders, which combine IRAK4 and IMiD substrate degradation. The STAT3 degrader was found to downregulate immune checkpoint signals on tumor cells and impact immune cells in the tumor microenvironment, resulting in in-vivo antitumor activity in a solid tumor model and lowering immunosuppression. IRAKIMiDs led to increased cell death compared to IMiDs or IRAK4 degraders alone and triggered promising in-vivo tumor regression in multiple models of MYD88-mutant B cell lymphoma. Degrading IRAK4 and IMiD substrates resulted in in-vitro cell growth inhibition.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.